Consultation Services

Arista Biologicals Inc. has extensive experience in developing assays for infectious disease, hormones, drugs of abuse, therapeutic drugs, environmental assays, and many other analyte types. Consultation services are available to clients who already possess proprietary assay technology, and require specific assistance or guidance in further developing those products. Please contact us with your specific requirements and we will be happy to provide a proposal for your consideration.

Feasibility Studies

Arista’s feasibility study service is for customers who wish to develop a specific assay. Feasibility studies are ideal for development of new assays, customization of existing assays or outsourcing the development work for proprietary antigens or antibodies.

This type of study is a simple and cost effective way to determine if available reagents are capable of being developed into a working lateral flow assay. With Arista Biological’s extensive experience developing all types of lateral flow assays, and industry standard manufacturing equipment, working with Arista combines great potential for a successful development with a high level of transferability.

Feasibility studies can be performed in as little as two weeks. Reagents can be either supplied by the customer or sourced by Arista Biologicals Inc. Feasibility studies are billed 50% in advance and 50% following the successful completion of the assay.

Custom Purification

Arista Biologicals has extensive experience with antibody purification. Arista offers custom purification service for customers who require affinity, Protein A, or other types of protein purifications for monoclonal and polyclonal antibodies. In close consultation with our clients, Arista can determine the best method to target the desired purity, yield and cost, specific to your application. Alternatively Arista can also follow an existing protocol customized to client specifications. Typical purification service takes 1-2 weeks to complete, depending on the purification method chosen. If your application requires an antibody of extremely high purity, an affinity support from your antigen is prepared and used for affinity chromatography. Our technical staff can conjugate even the most difficult antigen to purification support columns.

We are DEA licensed and able to produce drug and related reagents. All antibody purification and processing is performed using equipment and facilities in compliance with Good Manufacturing Practice (GMP) guidelines.

Custom Conjugation

Custom conjugation service of your antibody or protein is available for optimization. For the initial pilot conjugation, we require at least two milligrams to perform a thorough optimization, although we have been successful with as little as 200 micrograms in some cases. Please contact us for pricing.

Monoclonal Antibody Development

The monoclonal antibody development is divided into phases, with the option of halting the hybridoma production prior to the beginning of the next phase. The development phases are as follows:

Phase 1: Immunization

Immunization of mice (Balb/c) with antigen to stimulate antibody production. You may choose to follow our standard immunization protocol, or work with our staff to use your own protocol. Periodic serum samples are analyzed for antibody production using ELISA. If desired, clients can request serum samples for additional characterization. ELISA will be used to determine the highest titer mice to be used for cell fusion.

Phase 2: Fusion

Fusion of spleen cells with myeloma cell line. The fused cells are then placed in several 96-well culture plates. Viable colonies appear as early as 3-5 days after fusion and are kept healthy with a fresh supply of nutrient media as necessary.

Phase 3: Screening

When hybridoma colonies are large enough to screen, screening of all wells containing fusion products is done with ELISA assay. All positive wells will be expanded and frozen for parental hybridomas. The number of positives depends on the nature of the antigen, and can range from a few hybridomas to a dozen or more. Additional hybrids can be frozen for further studies.

Phase 4: Pilot Production

After positive hybridomas are selected for further development, they will be cloned using the limiting dilution method and screened by ELISA. Clones with the desired specificity will be expanded, or harvested for ascites production. Arista Biologicals will make every effort to provide the customer with this custom service in the shortest possible time. A period of three to nine months will normally be required for completion of the project. Delays may be incurred if the antigen is poorly immunogenic or produces unstable clones.

The success of the project is dependent upon the material used, supplied by either the customer or by our supplier. Arista Biologicals does not guarantee that the monoclonal antibodies produced will work in the client's own application. The client is responsible for determining the utility of these antibodies in their specific applications. The customer must do further testing to ensure applicability.

All clones, cell lines, antibodies and other materials which are the products of this project shall become the exclusive property of the client at the conclusion of the project. Full confidentiality is guaranteed.